Intra-arterial Cetuximab for Glioma

Phase-Based Progress Estimates
Glioma+10 More
Intra-arterial Cetuximab - Drug
All Sexes
What conditions do you have?

Study Summary

This trial is testing a new way to treat brain cancer that involves surgery, radiation, and chemotherapy. The goal is to see if this new method is safe and effective.

Eligible Conditions
  • Glioma
  • Brain
  • Anaplastic Astrocytoma (AA)
  • Neoplasms, Brain
  • Anaplastic Oligo-astrocytoma (AOA)
  • Malignant Neoplasms of Brain
  • Glioblastoma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Glioma

Study Objectives

2 Primary · 2 Secondary · Reporting Duration: 2 years

2 years
Overall Survival (OS)
6 months
Composite overall response rate (CORR) through the Response Evaluation Criteria In Solid Tumors (RECIST)
Progression Free Survival (PFS)
Toxicities graded according to the NCI Common Toxicity Criteria (CTCAE) version 4.03

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Other trials for Glioma

Trial Design

1 Treatment Group

Intra-arterial Cetuximab with Re-Irradiation
1 of 1
Experimental Treatment

37 Total Participants · 1 Treatment Group

Primary Treatment: Intra-arterial Cetuximab · No Placebo Group · Phase 2

Intra-arterial Cetuximab with Re-IrradiationExperimental Group · 3 Interventions: Intra-arterial Mannitol, Intra-arterial Cetuximab, Hypofractionated re-irradiation · Intervention Types: Drug, Drug, Radiation

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years

Who is running the clinical trial?

Northwell HealthLead Sponsor
420 Previous Clinical Trials
490,660 Total Patients Enrolled
5 Trials studying Glioma
512 Patients Enrolled for Glioma
John Boockvar, MD3.916 ReviewsPrincipal Investigator - Northwell Health
Northwell Health
11 Previous Clinical Trials
738 Total Patients Enrolled
2 Trials studying Glioma
442 Patients Enrolled for Glioma
5Patient Review
This neurosurgeon is nothing short of a hero. They are a miracle worker.

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
Patients must have a Karnofsky performance status ≥60% and an expected survival of ≥ three months.
You are a male or female patient of at least 18 years of age.
Patients must have at least one confirmed and evaluable tumor site.
You have a confirmed tumor site.
You have a coagulation profile that is less than 1.5 times the upper limit of normal.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 7th, 2021

Last Reviewed: October 4th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.